Results
|
9341.
|
|
|
9342.
|
|
|
9343.
|
|
|
9344.
|
|
|
9345.
|
|
|
9346.
|
|
|
9347.
|
|
|
9348.
|
|
|
9349.
|
|
|
9350.
|
|
|
9351.
|
|
|
9352.
|
|
|
9353.
|
Randomized Phase 2 Study of Trebananib (AMG 386) with or without Continued Anti-Vascular Endothelial Growth Factor Therapy in Patients with Renal Cell Carcinoma Who Have Progressed on Bevacizumab, Pazopanib, Sorafenib, or Sunitinib - Results of NCI/CTEP Protocol 9048. [electronic resource] by
- Semrad, Thomas J
- Groshen, Susan
- Luo, Chunqiao
- Pal, Sumanta
- Vaishampayan, Ulka
- Joshi, Monika
- Quinn, David I
- Mack, Philip C
- Gandara, David R
- Lara, Primo N
Publication details: Kidney cancer (Clifton, Va.) Feb 2019
In:
Kidney cancer (Clifton, Va.) vol. 3
Availability: No items available.
|
|
9354.
|
|
|
9355.
|
|
|
9356.
|
|
|
9357.
|
|
|
9358.
|
|
|
9359.
|
|
|
9360.
|
|